Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00281541 · ClinicalTrials.gov registry record · Phase 2
A Study for the Treatment of Unresectable Stage III or Metastatic Stage IV Melanoma
A Phase 2 study, sponsored by Astellas Pharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 29
- Enrollment target
NCT00281541 is a Phase 2 study that has completed, run by Astellas Pharma. The registered enrollment target is 29 participants.
The verdict
NCT00281541, a Phase 2 study, has completed, sponsored by Astellas Pharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 29 participants
- Enrollment target
Study Summary
A study with YM155 for the treatment of unresectable stage III or metastatic stage IV melanoma.
Interventions
- DRUG YM155
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2005-11 |
| Est. Completion | 2007-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00281541
The ClinicalTrials.gov registry entry for NCT00281541 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Astellas Pharma, which has 165 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which YM155 is the first listed.
NCT00281541 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00281541 about?
NCT00281541 is a clinical study titled "A Study for the Treatment of Unresectable Stage III or Metastatic Stage IV Melanoma". A study with YM155 for the treatment of unresectable stage III or metastatic stage IV melanoma.
What is the current status of trial NCT00281541?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 29 participants. The study started on 2005-11. Estimated completion is 2007-06.
What interventions are being tested in trial NCT00281541?
The interventions under investigation include: YM155 (DRUG).
Who is sponsoring clinical trial NCT00281541?
This trial is sponsored by Astellas Pharma, which has 165 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.